AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06596772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel (etanercept)
Description: Enbrel 50 mg/week via subcutaneous injection
Study NCT06656221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 2000mg on Cycle 1 Days 1-2
Study NCT06656221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is given intravenously at a dose of 2.5mg on Cycle 1 Day 8. Glofitamab is given intravenously at a dose of 10mg on Cycle 1 Day 15. Glofitamab is given intravenously at a dose of 30mg on Day 1 of Cycles 2-6
Study NCT06656221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is given intravenously at a dose of 1.6 mg/m² on Days 1, 8, and 15 of Cycles 1-12.
Study NCT06656221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib is given orally at a dose of 150 mg daily on Days 1-21 of Cycles 1-12.
Study NCT06612281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: colorectal cancer (CRC) screening
Description: Gixam test
Study NCT06612281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: colorectal cancer screening
Description: Fecal Immunochemistry Test (FIT)
Study NCT06612281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy after bowel cleansing
Description: Standard of care optical colonoscopy for colorectal cancer screening
Study NCT05154214 — intervention group
Intervention type: PROCEDURE
Intervention: Drug-induced sleep endoscopy directed surgery
Description: Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
Study NCT06616766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH42946
Description: YH42946
Study NCT06521853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK With Autogenous Bone Graft
Description: placement of PEEK With Autogenous Bone Graft
Study NCT06521853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK With Xenograft
Description: placement of PEEK With xenograft
Study NCT06674772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva test
Description: Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
Study NCT06779812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Surgery
Description: Carpal tunnel surgery is performed endoscopically, using smaller incisions. Endoscopic surgery is a minimally invasive method that allows for faster and less painful recovery
Study NCT06779812 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Carpal Tunnel Surgery
Description: Carpal tunnel surgery is performed endoscopically, using smaller incisions. Endoscopic surgery is a minimally invasive method that allows for faster and less painful recovery
Study NCT06586957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKT3964
Description: Oral CDK2 Degrader
Study NCT06051695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A2B694
Description: Autologous logic-gated Tmod CAR T cells
Study NCT06051695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: xT CDx with HLA-LOH Assay
Description: An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
Study NCT05911958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 for injection
Description: SHR-A1811 for injection
Study NCT06271499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization with USG
Description: Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of >50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
Study NCT06271499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization with smart glasses integrated UGG
Description: The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of >50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
Study NCT06678997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zinc-L carnosine/Polaprezinc
Description: This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
Study NCT06678997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thickened formula
Description: This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
Study NCT06546735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N0728
Description: 1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.
Study NCT06546735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesomni®
Description: 1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
Study NCT06779812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real auricolothery
Description: 3 days before the intervention, patients will have an auriculotherapy session with an experimental group
Study NCT06779812 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham auriculotherapy
Description: 3 days before the intervention, patients will have an auriculotherapy session with an sham group
Study NCT06781034 — intervention group
Intervention type: OTHER
Intervention: None, pure observational study
Description: None, pure observational study
Study NCT06781346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal Block
Description: In RI block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the medial border of the scapula between the 4th and 5th rib of the patients in the RIB group. In the ultrasound image, the trapezius muscle, rhomboid muscle, intercostal muscles,pleura, and lung were identified. Under the aseptic condition, inserted laterally in the plane of the T5 level guided by an ultrasound probe with an in plane technique. The intravascular injection should be confirmed negative through aspiration, and 1-3 ml of normal saline was injected to divide the rhomboid and intercostal muscle, and a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected After negative aspiration of blood or air, injected into the deep layer of the rhomboid muscle.
Study NCT06781346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: In the TPV block group , the transverse process and the pleura will be identified and needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards.
Study NCT05244928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®
Description: Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total.
Study NCT06062615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement using Omnibot Knee System
Description: total knee replacement with robotic assistance
Study NCT06062615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total knee replacement
Description: Conventional total knee replacement without robotic assistance
Study NCT06062615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibot Robotic Knee System
Description: utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
Study NCT04943822 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A new APP
Description: A new APP for prevention and treatment of complications of intestinal peristomal skin
Study NCT04943822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A new APP
Description: A new APP for prevention and treatment of complications of intestinal peristomal skin
Study NCT05860777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complexity score and implementation
Description: AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
Study NCT04619225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
Study NCT05285865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
Study NCT05285865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Mobilization
Description: Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
Study NCT06485557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus platinum-based chemotherapy
Description: The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
Study NCT06485557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus platinum-based chemotherapy
Description: The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
Study NCT06485557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab plus platinum-based chemotherapy
Description: The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
Study NCT06781372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Development and characterization of PDOs
Description: An amount of tissue of approximately 2-3 cm3, if available, will be allocated to the study. The specimen will be divided in three parts (depending on the volume of the biopsy) and used to: a) obtain PDOs according to established procedures (Chadwick, et al., 2020; Gamboa, et al., 2021); b) flash-frozen for molecular analysis of original tissue; c) used to isolate GSCs by flow-cytometry cell sorting. Only PDOs characterized by histological and molecular conformity with primary tumors will be used. The mutational status of genes frequently associated with GBM onset and progression will be analyzed in PDOs, and compared with data derived from tumor DNA, in order to assess their representation of the genetic heterogeneity of original tumors. These studies will allow us the set up a reliable procedure for the ex-vivo establishment of pre-clinical models of GBM.
Study NCT06781372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs
Description: PDOs and GSCs representing different GBM molecular subtypes will be treated with epigenetic modulators , with spliceosome inhibitors or with drugs that indirectly target the splicing machinery, such as PRMT5 inhibitors. These drugs will be tested for their ability to suppress growth and/or induce cell death, when administered either alone or in combination with standard chemotherapy. Furthermore, we will perform RNA sequencing experiments to identify TE-derived transcripts and splice variants induced by the treatments. By employing a computational pipeline developed in our laboratory (Pieraccioli and Sette, unpublished), we will also characterize the affinity for MHC-I and immunogenicity of neoepitopes encoded by the treatment-induced TE-derived transcripts and splice variants. The results of these analysis will allow to identify neoepitopes to be used for designing immunotherapy approaches.
Study NCT06623266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neck management
Description: In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.
Study NCT06623266 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Neck management
Description: In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.
Study NCT06676878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incremental exercise
Description: A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.
Study NCT06676878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incremental exercise
Description: A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.
Study NCT06685120 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP + HA injection
Description: Following autologous PRP harvesting and production, 5 mL of PRP and 40 mg/2 mL of HA will be infiltrated into the knee joint affected by gonarthrosis. The combined procedure will be performed by first infiltrating the hyaluronic acid, and next, leaving the needle inserted into the joint to avoid a second needle insertion, the PRP will be infiltrated, respecting the conditions of sterility. In this way, the two products will not be mixed in the same syringe.
Study NCT06685120 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Following autologous PRP harvesting and production, patients randomized into control group 1 will undergo single intra-articular PRP infiltration. Five mL of PRP will be infiltrated into the knee joint affected by gonarthrosis.
Study NCT06685120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA injection
Description: Patients randomized into control group 2, will undergo similar blood sampling as the PRP+ HA group and the PRP group to maintain blinding. They will then undergo intra-articular infiltration of 40 mg/ 2 ml HA into the knee with gonarthrosis.
Study NCT06684678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized automatic coaching message for glycemic management and depressive symptom
Description: For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management.
Study NCT06690203 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: NRICM102
Description: A traditional Chinese medicine formula
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib (LY3009104) 4 mg
Description: Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib 200mg/day
Description: Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Description: Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day
Study NCT06387433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile app use
Description: The experimental group will use the mobile application while controlled group will not use mobile application. Investigators will assess the effectiveness of mobile application in ensuring medication adherence and self-management among diabetics in Pakistan
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG
Description: Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib (LY3009104) 4 mg
Description: use of JAK inhibitor at full dose until the end of the protocol
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgotinib 200mg/day
Description: use of JAK inhibitor at full dose until the end of the protocol